• For printing use.
• June 21, 2024

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) has announced that it has achieved the performance indicators set for the 2023 fiscal year and will continue to implement the dementia screening program in Bunkyo-ku, Tokyo (hereinafter, the program) in the 2024 fiscal year for the promotion of awareness and early detection of dementia.

This program is a dementia screening for Bunkyo residents aged 55 to 75 in 5-year increments (approximately 12,300 people). It uses the digital cognitive function check tool "NoKNOW" to check the brain health, and based on the measurement results and the questionnaire of "NoKNOW", it provides advice from doctors, recommends visits to medical institutions, introduces support from visiting nurses and promotes participation in lifestyle improvement programs. As early detection and response to dementia are important, the program, which targets 55-year-olds, is one of the advanced examples of local government's efforts for early detection of dementia, as Tokyo recommends expanding the age range from over 70 years old to over 50 years old for dementia screening targets.Starting in fiscal year 2021, this program is being implemented as a priority policy in Bunkyo-ku, and Eisai has been entrusted with the program since the first year to provide "NoKNOW" and operational support for group screening. In fiscal year 2022, the performance-based private sector commissioning contract (PFS) was introduced, setting goals for the number of "NoKNOW" implementation and the average number of participants in the lifestyle improvement program as performance indicators. Eisai achieved both performance indicators for the second consecutive year in fiscal year 2023 by providing opportunities for trial implementation of "NoKNOW" and the exercise program "Brepa Size" developed by the company.

In fiscal year 2023, 245 people participated in the screening at the venue, and about 12% of them were recommended to visit medical institutions. In a questionnaire conducted after the screening, 52% of the 122 respondents said that they "think more positively about dementia than before," and 68% said that they "have become more interested in brain and health." Eisai is collaborating with local governments, medical associations and others nationwide to provide opportunities for measuring brain health according to local issues and to establish pathways to medical care and support. These efforts have been promoted in 60 local governments in fiscal year 2023. Going forward, we will contribute to the creation of a community where residents are aware of and check their brain health from a healthy state, and early detection, diagnosis, and preparation for dementia are possible, aiming to realize a "society that coexists with dementia" where people with dementia can live their lives as themselves.

PFS performance indicators for fiscal year 2023:

In addition, in fiscal year 2023, 245 people participated in the screening at the venue, and about 12% of them were recommended to visit medical institutions. In a questionnaire conducted after the screening, 52% of the 122 respondents said that they "think more positively about dementia than before," and 68% said that they "have become more interested in brain and health."

Reference materials:

Above.

1.

1. About 'Nou Know'.

'Nou Know' (non-medical device) is a tool that can check reaction speed, attention, visual learning, and memory through a simple card game test using a computer, tablet device, or smart phone. The user can check it alone and in a short time (about 15 minutes), and regular self-checks are possible in daily life and health checkups. It has been introduced in many health screening institutions, research institutions, local governments, companies, and universities.

For more information, please visit: Please visit https://nouknow.jp/ (implementation list https://nouknow.jp/partner/ ).Mazdutide (IBI362) is a GLP-1R/GCGR dual agonist jointly developed by Innovent Bio and Eli Lilly and Co. As a somatostatin analogue similar to human gastric inhibitory polypeptide (OXM), Mazdutide not only promotes insulin secretion, lowers blood sugar, and reduces weight by stimulating GLP-1R, but also increases energy consumption and enhances weight loss by stimulating GCGR, while improving liver fat metabolism. Mazdutide has shown excellent weight loss and hypoglycemic effects, as well as multiple metabolic benefits in reducing waist circumference, blood lipids, blood pressure, uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity, in multiple clinical studies. Currently, five Phase III clinical studies of Mazdutide are underway in Chinese overweight or obese participants (GLORY-1 and GLORY-2) and type 2 diabetes participants (DREAMS-1, DREAMS-2, and DREAMS-3). Among them, the GLORY-1 and DREAMS-2 studies have achieved their primary endpoints.

2. About pay-for-success private commission contract system.Pay-for-success private commission contract system (Pay For Success: PFS) is a new method of public-private partnership in which local governments entrust private businesses to solve administrative challenges by setting performance indicators that correspond to the improvement of the performance indicators evaluated by third parties. It is a promotion measure of the cabinet office, and it is expected to improve the quality of public services and reduce expenses.

3. About 'Blepa Size'.'Blepa Size' is a dual task exercise program that activates the body and brain by moving the limbs to the beat of the music and incorporating intellectual tasks. Our company developed it as an introductory exercise that can be started easily and enjoyably by people who are concerned about their brain health under the supervision of a doctor. It is used in health classes and online events organized by local governments.

For details, please visit the dementia information site 'Consultation e-65' operated by Theoria Technologies Co., Ltd., a subsidiary of Eisai Group (https://soudan-e65.com/maintenance/brain_exercise/).Mazdutide (IBI362) is a GLP-1R/GCGR dual agonist jointly developed by Innovent Bio and Eli Lilly and Co. As a somatostatin analogue similar to human gastric inhibitory polypeptide (OXM), Mazdutide not only promotes insulin secretion, lowers blood sugar, and reduces weight by stimulating GLP-1R, but also increases energy consumption and enhances weight loss by stimulating GCGR, while improving liver fat metabolism. Mazdutide has shown excellent weight loss and hypoglycemic effects, as well as multiple metabolic benefits in reducing waist circumference, blood lipids, blood pressure, uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity, in multiple clinical studies. Currently, five Phase III clinical studies of Mazdutide are underway in Chinese overweight or obese participants (GLORY-1 and GLORY-2) and type 2 diabetes participants (DREAMS-1, DREAMS-2, and DREAMS-3). Among them, the GLORY-1 and DREAMS-2 studies have achieved their primary endpoints.

• Full release